Gilead Sciences (GILD) has positioned itself at the front line in the global war against COVID-19. The biotech’s experimental drug remdesivir is currently in two Gilead sponsored Phase 3 trials in over 90 locations, and two further investigator sponsored Phase 3 trials in China. The drug is currently registered in 11 ongoing trials, from which a handful of data readouts are expected in the next 2 to 6 weeks.So far, remdesivir has shown powerful in vitro efficacy against RNA viruses in cell-based assays and evidence of efficacy in both in California and Washington states; Additionally, there has also been some …read more
Source:: Yahoo Finance
